Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Godinot

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Liver|February 1, 1995
The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trialJ L Gaudin, P Faure, H Godinot, et al.
Journal of Hepatology|January 1, 1993
Simultaneous steroids/interferon therapy in chronic hepatitis BX Causse, H Godinot, M Chevallier, et al.
Gastroenterology|August 1, 1991
Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitisX Causse, H Godinot, M Chevallier, et al.
Experimental Hematology|July 25, 2000
Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitutionM Michallet, T Philip, I Philip, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Liver|February 1, 1995
The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trialJ L Gaudin, P Faure, H Godinot, et al.
Journal of Hepatology|January 1, 1993
Simultaneous steroids/interferon therapy in chronic hepatitis BX Causse, H Godinot, M Chevallier, et al.
Gastroenterology|August 1, 1991
Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitisX Causse, H Godinot, M Chevallier, et al.
Experimental Hematology|July 25, 2000
Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitutionM Michallet, T Philip, I Philip, et al.
Pageof 1